



**Study protocol**

# **High-flow Nasal Oxygen versus Non-invasive CPAP Ventilation Support for Hypercapnic Respiratory Failure (The HIGH-for-HYPER study)**

**Study group**

Dominik Roth  
Verena Fuhrmann  
Michael Schwameis  
Nina Buchtele  
Calvin Kienbacher  
Roberta Laggner  
Harald Herkner  
Anton N. Laggner

**Contact**

Priv. Doz. Dr. med. univ. et. scient. med.  
Dominik Roth  
Universitätsklinik für Notfallmedizin  
Medizinische Universität Wien  
Spitalgasse 23  
A-1090 Vienna, Austria  
Tel: + 43 1 / 40400-19640  
Fax: + 43 1 / 40400-19650  
Email: dominik.roth@meduniwien.ac.at

## Background

### Hypercapnic respiratory failure

Respiratory failure is a leading cause of morbidity and mortality, and one of the most frequently encountered problems at the emergency department<sup>1,2,3</sup>.

Hypercapnic or hypercarbic respiratory failure, also dubbed respiratory failure type II, is characterized by failure of the respiratory system in one of its two gas exchange functions: carbon monoxide ( $\text{CO}_2$ ) elimination. It is thus usually defined via partial pressure of  $\text{CO}_2$  in the arterial blood gas ( $\text{PaCO}_2$ ), a value of higher than 50mmHg being a commonly used cut-off<sup>4,5</sup>.

Hypercapnic respiratory failure is often associated with severe airway disorders, such as asthma and chronic obstructive pulmonary disease (COPD), but might also be found in other situations, where respiratory drive is restricted, such as intoxications, neuromuscular diseases or chest wall abnormalities<sup>4,5</sup>.

Hypercapnic respiratory failure, i.e. respiratory failure type II, is often associated with hypoxic respiratory failure, i.e. respiratory failure type I, failure of oxygenation, however type I failure is also often observed without hypercapnia<sup>4,5</sup>.

Respiratory failure, both type I and II, may be further classified into either acute or chronic. Distinction between both forms is often not easy, and, in addition to arterial blood gas analysis, might require additional tests to identify clinical markers such as polycythemia or cor pulmonale. For practical reasons, acute respiratory failure is often defined as a situation, in which respiratory failure develops too fast to allow for renal compensation and an increase in bicarbonate ( $\text{HCO}_3^-$ ) levels, and thus leading to acidosis (pH less than 7.3)<sup>4,5</sup>.

Therapy strategies for hypercapnic respiratory failure include non-invasive CPAP ventilation support, intubation and mechanical ventilation (both assisted and controlled forms)<sup>4,5</sup>, and, in very severe cases, extracorporeal methods, such as extracorporeal life support systems<sup>6,7</sup>.

## Non-invasive CPAP Ventilation Support

Non-invasive CPAP ventilation support via either helmets, or different kinds of tight masks, is the current method of choice for the treatment of patients with acute respiratory failure in the intensive care setting. Eligible patients include those with an intact airway, airway-protective reflexes, who are alert enough to follow commands, whereas patients who lack those criteria require immediate intubation<sup>4,5</sup>.

Non-invasive CPAP ventilation support improves both oxygenation (by providing an inspired fraction of oxygen (FiO<sub>2</sub>) of 100%, which is not possible via a simple venturi-mask, and the possibility of positive end-expiratory pressure (PEEP), preventing collapsing of the alveoli), and decarboxylation (by increasing tidal volume). It has been shown to decrease both need for intubation and in-hospital mortality<sup>8</sup>.

Non-invasive CPAP ventilation support however requires a high grade of skill from providers, and intensive communication with the patient to explain to him the usefulness of a tight-fitting device in his face in a situation of perceived massive dyspnea. Although severe adverse effects of non-invasive CPAP ventilation support are very rare, pain and pressure marks may occur. Despite all efforts of care providers, there is a relevant fraction of patients who do not tolerate ventilation support via a tight mask at all. Brochard et al. report 15% of patients not tolerating the therapy, with an additional 25% of patients presenting with contraindications. These might include general contraindications against non-invasive techniques, such as aforementioned lack of airway-protective reflexes, but also such specific for tight masks, such as anatomical abnormalities of the face<sup>8,9</sup>.

## High-flow Nasal Oxygen

High-flow nasal oxygen (HFNO<sub>2</sub>) therapy is usually applied via a wide-bore nasal cannula. It provides up to 60L/min of a heated and humidified gas mixture (at an adjustable mix medical of oxygen and room air). This therapy is much less invasive for the patient, and thus often better tolerated.

HFNO<sub>2</sub> has been increasingly used in the last years for hypoxic respiratory failure (i.e. type I failure), and numerous studies have shown its efficiency in this indication both at the intensive care unit and at the emergency

department<sup>10-15</sup>. A recent systematic review and meta-analysis has concluded in improved patient comfort and reduced dyspnea scores<sup>16</sup>.

Despite this good evidence for HFNO<sub>2</sub> in hypoxic respiratory failure, it has only reluctantly been used for hypercapnic respiratory failure. This might in a large part be explained by the fact that patients with chronic hypercapnia are known to diminish their respiratory drive when exposed to hyperoxia<sup>17</sup>. However, evidence has begun to change on this indication in recent time. HFNO<sub>2</sub> has been shown to generate PEEP, despite not being a closed system<sup>18</sup>, and to improve CO<sub>2</sub> clearance by flushing anatomical dead space<sup>19</sup>. It might also help to reduce inspiratory resistance and facilitate secretion clearance from humidified gas<sup>20</sup>. A study on COPD patients showed an increase in breathing pressure amplitude and mean pressure, as well as tidal volume, with a trend towards reduction of pCO<sub>2</sub><sup>21</sup>.

Based on these findings, the use of HFNO<sub>2</sub> has increased in clinical practice, and a number of case reports and -series indicate successful use<sup>22-24</sup>. Fraser et al. successfully investigated the use of HFNO<sub>2</sub> in patients with chronic COPD<sup>25</sup>, and Jeong et al. retrospectively analyzed changes in arterial blood gases during use of HFNO<sub>2</sub> in the ED for both hypercapnic and non-hypercapnic patients, and found a significant reduction of pCO<sub>2</sub><sup>26</sup>.

There is, however, to date no randomized controlled trial investigating the effect of HFNO<sub>2</sub> in acute hypercapnic respiratory failure.

### Objectives

To assess the efficacy and safety of HFNO<sub>2</sub> versus non-invasive CPAP ventilation support in acute hypercapnic respiratory failure.

**Formatiert:** Tiefgestellt

## Study

### Setting

The study will be performed as a randomized controlled on-inferiority trial.

The study site is the Department of Emergency Medicine (ED) of the Vienna General Hospital, a leading academic research center for emergency medicine at a large, tertiary care hospital.

Around 90,000 patients are being treated at the department each year, approximately 150-200 of them suffering from hypercapnic respiratory failure, and requiring non-invasive ventilation support.

The department features its own ICU and intermediate-care unit, with 7 positions each, for a total of 14 positions capable of providing CPAP therapy. The Airvo II HFNO<sub>2</sub>-device is also at regular use at the department.

### Sponsoring

Sponsor of this study will be the Department of Emergency Medicine at the Medical University Vienna. There is no industry sponsoring or industrial financial support, but we will apply for financial support from research grants.

### Registration and Regulation

This project is considered as a study investigating differences of two standard medical methods. This study will be submitted for review and approval to the ethical committee of the Medical University Vienna and the Vienna General Hospital. The office of the medical Director will be announced, and the study will be registered at <http://www.controlled-trials.com/>.

## Population

### Inclusion criteria

- Adult patients (e.g. at least 18 years old) treated at the Emergency Department
- Acute hypercapnic respiratory failure defined as a  $pCO_2 > 50 \text{ mmHg}$  and a  $\text{pH} < 7.3$  on admission

### Exclusion criteria

- Patients being comatose on admission, with no intact airway, lack of airway-protective reflexes, or those who are not alert enough to follow commands
- Patients intubated by Emergency Medical Service
- Patients requiring intubation on admission
- Pregnant women

## Outcome

### Primary outcome

- Reduction of  $pCO_2$  per hour

### Secondary outcomes

#### Clinical and safety Parameters

- Frequency of therapy failure (switch to other therapy; intubation)
- Patient's perception of the therapy (10-point Likert-Scale from very uncomfortable to very comfortable)
- Adverse events

#### Efficacy Parameters:

- Time until  $pCO_2$  reaches 50mmHg or less

#### Economic Parameters:

- Length of Stay at the Emergency Department

- Frequency of admission to ICU
- Frequency of admission to regular ward
- Length of Stay at the ICU
- Length of Stay at the Hospital
- Hospital readmission within 1 month

## Methods

### Randomisation

A random sequence will be generated by a person not involved in the enrolment of patients using standard software. Randomisation will be performed in variable blocks of 4 to 6, to yield an unpredictable allocation yet warranting balanced group sizes.

Sequentially numbered sealed opaque envelopes (SNOSE), containing allocation either to the intervention or the control group, will be pre-produced. The envelopes will be opened after consent immediately before the start of the intervention to allow for allocation concealment and reduce the risk of immediate post-random exclusion.

### Intervention

Control consists of HFNO<sub>2</sub> using the Airvo II, Fisher & Paykel, New Zealand. A gas flow 60L/min and a FiO<sub>2</sub> as clinically feasible will be used. Therapy will be continued until a COHb-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.

### Control

Control consists of non-invasive CPAP ventilation support using a tight mask and standard respirator equipment of the Department of Emergency Medicine (Servo Ventilator 300, Siemens-Elema AB, Life Support Systems Division, Solna, Sweden). A positive airway pressure of 5cm H<sub>2</sub>O and a FiO<sub>2</sub> as clinically feasible will be used. Therapy will be continued until a COHb-level

of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.

Based on treating physician's judgement, both intervention and control treatments might be aborted at any time, and any other therapy (simple Venturi-Mask, HFNO<sub>2</sub>, non-invasive CPAP-ventilation support, intubation, extracorporeal methods) might be initiated.

#### Measurement

Baseline characteristics and demographic variables will include age, sex, smoking status, prior diseases, especially any history of COPD or Asthma, and duration of treatment of those, medication, body size, pre-hospital treatment. pCO<sub>2</sub> levels will be measured using blood gas analysis at 0 – 15 – 30 – 45 – 60 – 90 – 120 (and every 30 minutes thereafter) minutes after the beginning of the therapy, and at the end of the therapy.

Patient's perception of the therapy will be assessed after the end of the therapy using a 10-point Likert-Scale from very uncomfortable to very comfortable.

In case of abortion of assigned therapy, we will follow a carry-on-latest principle, by calculating pCO<sub>2</sub> reduction per hour by dividing actual reduction of pCO<sub>2</sub> during assigned therapy by total treatment time (including follow-on therapy after abortion), to achieve a maximally conservative interpretation of therapy effect.

## Statistics

### Sample size

Sample size considerations are based on the primary outcome  $pCO_2$  reduction per hour. Based on the published literature, we assume that the outcome in the control group is  $4\pm3$  mmHg/hour<sup>8</sup>. Based on a clinically assumed non-inferiority of 2mmHg we would need 28 experimental subjects and 28 control subjects to be able to reject the null hypothesis, that the lower limit of a two-sided 90% confidence interval of the true difference between two groups is above the non-inferiority limit, at a power of 80%. Formally we will have to enrol 56 patients. To allow for potential loss to follow up, missing data, measurement issues, or other design factors we will increase actual sample size to 62.

In terms of feasibility, we expect approximately 150 to 200 eligible patients within one year, resulting in an expected study-duration of approximately 6 months.

### Data Analysis

Baseline data and demographics will be tabulated for the intervention- and control-group to assess success of randomisation. Reduction of  $pCO_2$  per hour will be calculated by dividing delta  $pCO_2$  at start of therapy to end of therapy by duration of therapy in hours. In case of abortion of assigned therapy, we will follow a carry-on-latest principle, by calculating  $pCO_2$  reduction per hour by dividing actual reduction of  $pCO_2$  during assigned therapy by total treatment time. Reduction of  $pCO_2$  per hour will be compared between individuals in the intervention and individuals in the control group. Primary analysis will follow the intention-to-treat principle. The unit of analysis will be single persons. We will calculate effects as differences with 95% confidence intervals. For hypothesis tests we will use the t-test or Mann-Whitney-U-test, as appropriate. In case of relevant clustering we will use regression-based approaches.

Categorical secondary outcomes will be analysed by calculating relative risks with exact standard error based 95% confidence intervals, and the Fisher's exact test will be used for comparison. Continuous secondary outcomes will be analyzed like the primary outcome. Length of stay data are expectedly lognormally distributed, therefore we plan to use log-transformed values for further calculations.

For data analysis we will use Stata 11. A two-sided p-value less 0.05 is generally considered statistically significant.

#### 1.1.1.1 Privacy and Data safety

Directly and indirectly patient-related data will be stored physically and logically separated. In addition, only members of the study-group will have access to study data. Data will be stored on a secured computer of the department of emergency medicine and will be accessible only via restricted access for members of the study-group.

## Literature

1. Khan NA, Palepu A, Norena M, et al. Differences in hospital mortality among critically ill patients of Asian, Native Indian, and European descent. *Chest*. 2008 Dec; 134(6):1217-22.
2. Moss M, Mannino DM. Race and gender differences in acute respiratory distress syndrome deaths in the United States: an analysis of multiple-cause mortality data (1979- 1996). *Crit Care Med*. 2002 Aug; 30(8):1679-85.
3. Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. *Am J Respir Crit Care Med*. 2009 Feb 1; 179(3):220-7.
4. Kallstrom TJ, American Association for Respiratory Care. AARC Clinical Practice Guideline: oxygen therapy for adults in the acute care facility: 2002 revision & update. *Respir Care* 2002;47(6):717-720.
5. O'Driscoll BR, Howard LS, Davison AG. Emergency oxygen use in adult patients: concise guidance. *Clin Med* 2011;11(4):372-375.
6. Lewandowski K. Extracorporeal membrane oxygenation for severe acute respiratory failure. *Crit Care* 2000; 4: 156.
7. Schellongowski P, Riss K, Staudinger T, et al. Extracorporeal CO<sub>2</sub> removal as bridge to lung transplantation in life-threatening hypercapnia. *Transpl Int*. 2015 Mar;28(3):297-304.
8. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1995 Sep 28; 333(13): 817-822.
9. Tsolaki V, Pastaka C, Kostikas K, Karetzi E, Dimoulis A, Zikiri A, Koutsokera A, Gourgoulianis KI: Noninvasive ventilation in chronic respiratory failure: effects on quality of life. *Respiration* 2011; 81: 402-410.
10. Rittayamai N, Tscheikuna J, Praphruetkit N, et al. Use of High-Flow Nasal Cannula for Acute Dyspnea and Hypoxemia in the Emergency Department. *Respir Care* 2015;60(10):1377-1382.
11. Sztrymf B, Messika J, Mayot T, et al: Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: A prospective observational study. *J Crit Care* 2012; 324:324.e9-e13

12. Rello J, Pérez M, Roca O, et al; CRIPS Investigators: High-flow nasal therapy in adults with severe acute respiratory infection: A cohort study in patients with 2009 influenza A/H1N1v. *J Crit Care* 2012; 27:434-439
13. Roca O, Riera J, Torres F, et al: High-flow oxygen therapy in acute respiratory failure. *Respir Care* 2010; 55:408-413
14. Atwood C, Miller T, McMillan N et al: Effect of high flow highly humidified air via nasal cannula on respiratory effort in patients with advanced COPD. *Chest* 2011; 140:536A
15. Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, Ricard JD. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. *Intensive Care Med* 2011;37(11):1780-1786.
16. Monro-Somerville T, Sim M, Ruddy J, Vilas M, Gillies MA. The Effect of High-Flow Nasal Cannula Oxygen Therapy on Mortality and Intubation Rate in Acute Respiratory Failure: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2017 Apr;45(4):e449-e456.
17. Sassoon CS, Hassell KT, Mahutte CK. Hyperoxic-induced hypercapnia in stable chronic obstructive pulmonary disease. *Am Rev Respir Dis*. 1987 Apr;135(4):907-11.
18. Parke, R., McGuinness, S., Eccleston, M. Nasal high-flow therapy delivers low level positive airway pressure. *Br J Anaesth* 2009; 103: 886-890.
19. Ricard, J. High flow nasal oxygen in acute respiratory failure. *Minerva Anesthesiol* 2002; 78: 836-841.
20. Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. *Respir Med* 2009;103(10):1400-1405.
21. Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H: Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. *Respiration* 2013; 85: 319-325.
22. Pavlov I, Plamondon P, Delisle S. Nasal high-flow therapy for type II respiratory failure in COPD: A report of four cases. *Respir Med Case Rep*. 2017 Jan 1;20:87-88.

23. Lepere V, Messika J, La Combe B, Ricard JD. High-flow nasal cannula oxygen supply as treatment in hypercapnic respiratory failure.
24. Millar J, Lutton S, O'Connor P. The use of high-flow nasal oxygen therapy in the management of hypercarbic respiratory failure. Ther Adv Respir Dis. 2014 Apr;8(2):63-4.
25. Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax. 2016 Aug;71(8):759-61.
26. Jeong JH, Kim DH, Kim SC, et al. Changes in arterial blood gases after use of high-flow nasal cannula therapy in the ED. Am J Emerg Med. 2015 Oct;33(10):1344-9.